TIDMPXS
RNS Number : 8709D
Provexis PLC
12 July 2016
12 July 2016 Provexis plc
Study publication - Fruitflow(R): the first European Food Safety
Authority-approved
natural cardio-protective functional ingredient
Provexis plc ("Provexis" or the "Company"), the business that
develops, licenses and sells the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is pleased to
confirm the publication of an important study for Fruitflow(R) in
the European Journal of Nutrition.
The study, titled 'Fruitflow(R): the first European Food Safety
Authority-approved natural cardio-protective functional ingredient'
includes a scientific summary of the entire Fruitflow(R) project
from its inception and it is expected to be a significant
opportunity to promote Fruitflow(R) further across scientific,
trade customer and consumer channels. The study is available to
view on the Company's website at
www.provexis.org/wp-content/uploads/2016/07/Fruitflow%C2%AE-the-first-European-Food-Safety-Authority-approved-natural-cardio-protective-functional-ingredient-07-Jul-16.pdf
Fruitflow(R) is a patented, scientifically-proven tomato extract
which inhibits platelet aggregation, a known cause of heart attack,
stroke and venous thrombosis. It is a natural product classified as
a food which is easy to digest.
In May 2009 Fruitflow(R) was the first technology to be
substantiated by the European Food Safety Authority ('EFSA') under
the new Article 13(5) for proprietary and emerging science. In
December 2009 the European Commission authorised the health claim
'Helps maintain normal platelet aggregation, which contributes to
healthy blood flow'.
In 8 human trials, consumption of Fruitflow(R) has been proven
to maintain healthy platelet aggregation and improve blood flow. In
the largest single study for Fruitflow(R), positive effects were
observed in 97% of individuals tested. This compares favourably
with single-drug therapies such as aspirin which can be ineffective
in up to 30% of individuals; further, there are no recorded side
effects from Fruitflow(R).
On 31 May 2016 the Company announced in a trading update that
more than 50 regional consumer healthcare brands containing
Fruitflow(R) have now been launched by direct customers of DSM,
with a number of further regional brands having been launched
through DSM's distributor channels.
On 29 June 2016 the Company announced the launch of its new
Fruitflow(R) + Omega-3 dietary supplement product, which is
exclusively available through the Company's new e-commerce website
www.fruitflowplus.com, the product also has a Facebook page at
www.facebook.com/FruitflowPlus
Fruitflow(R)+ Omega-3 is a two-in-one supplement in an easy to
take capsule, supporting healthy blood flow and normal heart
function. The added ingredient of Omega-3 has a separate, positive
European Commission approved health claim: 'Omega-3 Fish Oil EPA
and DHA contribute to the normal function of the heart'.
Fruitflow(R)+ Omega-3 offers the first natural, safe,
scientifically proven solution for healthy blood flow and
cardiovascular health. It can be used in primary prevention for
healthy adults who understand the dangers of CVD and who want to
take control of their diet and lifestyle to maintain cardiovascular
health.
Fruitflow(R) and Fruitflow(R) + Omega-3 marketing
initiatives
The Company and DSM are committed to a number of ongoing
scientific and marketing initiatives for Fruitflow(R) and the
Company's Fruitflow(R) + Omega-3 capsules, seeking to extend the
reach of the existing science for Fruitflow(R) and give the
products further global exposure. Scientific and marketing
initiatives include:
-- A Key Opinion Leaders' roundtable in September 2016, which is
expected to be a good opportunity to promote Fruitflow(R) more
widely across key digital and other mainstream media channels; the
event will be supported by a broader consumer PR campaign.
-- A digital marketing strategy which is in the process of being
implemented, seeking to drive and optimise online leads and sales.
Fruitflow(R)+ Omega-3 capsules will be promoted across DSM's key
digital communities and channels, to include boosted posts on DSM's
Facebook channels targeting health conscious consumers.
-- DSM's product video for Fruitflow(R) which is available to view via the Company's websites www.provexis.com and www.fruitflowplus.com
-- The Company remains in the process of submitting some of the
underlying scientific studies for Fruitflow(R) for publication in
appropriate scientific journals, to include the Company's Aspirin
Comparison Human Trial for Fruitflow(R), with further study
publications envisaged in due course.
-- The Company's two stage collaboration agreement with the
University of Oslo undertaking further research into the
relationship between Fruitflow(R) and blood pressure regulation.
The Company and the University are in the process of conducting the
second stage of the collaboration work involving a small clinical
trial in Oslo by way of a proof of principle study. The Company and
the University expect to be able to complete the clinical trial in
the next few months and the results of the proof of principle study
will be announced as soon as possible thereafter.
Dawson Buck, Chairman of Provexis, commented:
"We are delighted to announce the publication of this important
study which is expected to be a significant opportunity to promote
Fruitflow(R) further across scientific, trade customer and consumer
channels.
The Company and DSM are committed to a number of ongoing
scientific and marketing initiatives for Fruitflow(R) and the
Company's Fruitflow(R) + Omega-3 capsules, seeking to extend the
reach of the existing science for Fruitflow(R) and give the
products further global exposure.
The publication of this study is another strongly positive
development for Fruitflow(R) and the business."
-ends-
For further information please contact:
Provexis plc Tel: 07490 391888
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development and licensing
of its proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient.
In May 2009, the Company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ("EFSA")
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim "Helps maintain normal platelet aggregation, which
contributes to healthy blood flow", which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 50 regional consumer healthcare brands now having been
launched by direct customers of DSM, and with a number of further
regional brands having been launched through DSM's distributor
channels.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
On 29 June 2016 the Company launched a high quality dietary
supplement product containing Fruitflow(R) and Omega-3 which is
being sold initially from a separate, dedicated website
www.fruitflowplus.com on a mail order basis.
The Company is engaged in a two stage collaboration agreement
with the University of Oslo ('the University') to undertake further
research into the relationship between Fruitflow(R) and blood
pressure regulation. The Company is very pleased with the
encouraging results from the first stage of the collaboration with
strong evidence that a standard dose of Fruitflow(R) has the
potential to give a clinically relevant reduction in systolic blood
pressure. The Company and the University are now in the process of
conducting a small clinical trial by way of a proof of principle
study.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXXFFELKEFF
(END) Dow Jones Newswires
July 12, 2016 02:00 ET (06:00 GMT)
Provexis (LSE:PXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2023 to Apr 2024